Journal: Molecular Therapy. Nucleic Acids

Article Title: A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation

doi: 10.1016/j.omtn.2019.12.023

Figure Lengend Snippet: Effects of FBRP on Expression Levels of Candidate Targets Involved in PI3K/AKT/NF-κB Signaling in Liver Tissues of DEN-Induced HCC Rats (A) Western blots of the candidate targets of FBRP against HCC involved in PI3K/AKT/NF-κB signaling. (B–M) Relative protein expression levels of (B) p-PI3K, (C) p-AKT, (D) IKκB, (E) p-IKκB, (F) the ratio of p-IKκB to IKκB, (G) NF-κB (p65), (H) p-NF-κB (p65), (I) the ratio of NF-κB (p65) to p-NF-κB (p65), (J) CCND1, (K) CCNE1, (L) CDK2, and (M) CDK4 in different groups are shown. Data are expressed as the mean ± SD. # p < 0.05, ## p < 0.01, ### p < 0.001, comparison with the normal group; @ p < 0.05, @@ p < 0.01, @@@ p < 0.001, comparison with the DEN-12w group; *p < 0.05, **p < 0.01, ***p < 0.001, comparison with the DEN-15w group; $ p < 0.05, $$ p < 0.01, $$$ p < 0.001, comparison with the DEN-18w group.

Article Snippet: The detailed information on these antibodies is as follows: p-PI3K (catalog no. 4249, Cell Signaling Technology, MA, USA), p-AKT (catalog no. 4060, Cell Signaling Technology, MA, USA), IKκB (catalog no. 8943, Cell Signaling Technology, MA, USA), p-IKκB (catalog no. YP0637, ImmunoWay, TX, USA), NF-κB (p65) (catalog no. YP0191, ImmunoWay, TX, USA), p-NF-κB (p65) (catalog no. 3033, Cell Signaling Technology, MA, USA), CCND1 (catalog no. 2978, Cell Signaling Technology, MA, USA), CCNE1 (catalog no. 20808, Cell Signaling Technology, MA, USA), CDK2 (catalog no. 10122-1-AP, Proteintech, IL, USA), CDK4 (catalog no. 11026-1-AP, Proteintech, IL, USA), and GAPDH (catalog no. 2118, Cell Signaling Technology, MA, USA).

Techniques: Expressing, Western Blot

Journal: Molecular Therapy. Nucleic Acids

Article Title: A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation

doi: 10.1016/j.omtn.2019.12.023

Figure Lengend Snippet: Effects of FBRP on Expression Levels of Candidate Targets Involved in PI3K/AKT/NF-κB Signaling in the HCC Cell Line Huh7 (A) Western blots of the candidate targets of FBRP against HCC involved in PI3K/AKT/NF-κB signaling in different groups. (B–M) Relative protein expression levels of (B) p-PI3K, (C) p-AKT, (D) IKκB, (E) p-IKκB, (F) the ratio of p-IKκB to IKκB, (G) NF-κB (p65), (H) p-NF-κB (p65), (I) the ratio of NF-κB (p65) to p-NF-κB (p65), (J) CCND1, (K) CCNE1, (L) CDK2, and (M) CDK4 in different groups are shown. Data are expressed as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, comparison with the Huh7 group; # p < 0.05, ## p < 0.01, ### p < 0.001, comparison with the Huh7-FBRP treatment group; @ p < 0.05, @@ p < 0.01, @@@ p < 0.001, comparison with the Huh7-LY294002 group.

Article Snippet: The detailed information on these antibodies is as follows: p-PI3K (catalog no. 4249, Cell Signaling Technology, MA, USA), p-AKT (catalog no. 4060, Cell Signaling Technology, MA, USA), IKκB (catalog no. 8943, Cell Signaling Technology, MA, USA), p-IKκB (catalog no. YP0637, ImmunoWay, TX, USA), NF-κB (p65) (catalog no. YP0191, ImmunoWay, TX, USA), p-NF-κB (p65) (catalog no. 3033, Cell Signaling Technology, MA, USA), CCND1 (catalog no. 2978, Cell Signaling Technology, MA, USA), CCNE1 (catalog no. 20808, Cell Signaling Technology, MA, USA), CDK2 (catalog no. 10122-1-AP, Proteintech, IL, USA), CDK4 (catalog no. 11026-1-AP, Proteintech, IL, USA), and GAPDH (catalog no. 2118, Cell Signaling Technology, MA, USA).

Techniques: Expressing, Western Blot

Journal: Scientific Reports

Article Title: Salidroside alleviates hepatic ischemia–reperfusion injury during liver transplant in rat through regulating TLR-4/NF-κB/NLRP3 inflammatory pathway

doi: 10.1038/s41598-022-18369-4

Figure Lengend Snippet: Antibodies for immunofluorescence staining and western blot.

Article Snippet: p-IKKβ , WB (1/1000) , Beyotime.

Techniques: Immunofluorescence, Staining, Western Blot, Concentration Assay

Journal: Cancer Cell International

Article Title: Phenyllactic acid promotes cell migration and invasion in cervical cancer via IKK/NF-κB-mediated MMP-9 activation

doi: 10.1186/s12935-019-0965-0

Figure Lengend Snippet: Effects of IKK-β on PLA-induced MMP-9 expression in cervical cancer cells. a ‒ c SiHa ( a ), HeLa ( b ), and C-33A ( c ) cells were treated with 10 mM PLA for the indicated times, and the activation of IKK-β was then examined by Western blot analysis. d ‒ f SiHa ( d ), HeLa ( e ), and C-33A ( f ) cells were pretreated with 10 μM IMD0354 (IMD, an inhibitor of IKK-β) for 90 min and then stimulated with 10 mM PLA for an additional 24 h. The expression of MMP-9 was measured by Western blot analysis. g ‒ h HeLa ( g ) and C-33A ( h ) cells were pretreated with 10 μM PD (ERK1/2 inhibitor), LY (PI3K/Akt inhibitor), H89 (PKA inhibitor), or GF (the inhibitor of PKC) for 90 min and then stimulated with 10 mM PLA for another 24 h. The activation of IKK-β were examined by Western blot analysis. i , j HeLa ( i ) and C-33A ( j ) cells were pretreated with 10 μM PD, LY, H89, or GF for 90 min, and then stimulated with 10 mM PLA for another 24 h. The expression of MMP-9 were examined by Western blot analysis. GAPDH expression was evaluated as a loading control. One representative of three different experiments, for each of the analyses performed, is shown

Article Snippet: Blots were incubated with the indicated primary antibodies against HPV16/18 E6 (ab70), HPV16 E7 (ab30731), and HPV18 E7 (ab100953) (Abcam, London, UK) and against MMP-1 (BS1229), MMP-2 (BS1236), MMP-3 (BS6243), MMP-9 (BS1241), MMP-10 (BS7167), MMP-13 (BS6668), IκBα (BS1190), p-IκBα (phospho-S32/S36, BS4105), p65 (BS1253), p-p65 (phospho-S536, BS4138), IKK-β (BS1756), and p-IKK-β (phospho-S180/181, BS4237) (Bioworld Technology, Nanjing, China) at 4 °C overnight, followed by incubation with a goat anti-rabbit (ab6721) or rabbit anti-mouse (ab6728) IgG secondary antibody (Abcam, London, UK) for 1 h at room temperature.

Techniques: Expressing, Activation Assay, Western Blot